B
Bristol-Myers Squibb
Biopharmaceutical medicines for patients with serious diseases
About Bristol-Myers Squibb
Bristol Myers Squibb discovers, develops and supplies medicines for patients with serious diseases. Its therapeutic focus includes oncology, hematology, neuroscience, immunology and cardiovascular disease.
It generates revenue primarily from medicine sales worldwide, principally to wholesalers, distributors and specialty pharmacies, with additional sales to retailers, hospitals, clinics, government agencies and patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 1929
- Employees
- 38,633
- Open positions
- 488
- Dealroom signal
- 71.3/100
- Industry
- Health, Transportation
- Sub-industry
- Pharmaceutical
- Sector
- Charity, Performance Management, Tourism, Biotechnology, Drug Development, Anti-Fraud, Pay Per Result, Horizon Europe
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 131 companies, latest Jul 2026
- Capital deployed
- $7.5B
- Preferred round
- SERIES B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Nov 2025 | $5B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Feb 2024 | $13B | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Bristol-Myers Squibb is 790K monthly website visits, down 10.2% over the last three months. Bristol-Myers Squibb's team grew 30.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
BayerGlobal enterprise with core competencies in the Life Science fields of health care and agriculture |
Leverkusen, Germany | Operational | 92,539 | — | $85B |
Seven BridgesA cloud-based environment for conducting bioinformatic analyses |
New Belgrade Urban Municipality, Serbia | Acquired | |||
NumaresIn vitro diagnostic tests and test systems for high-throughput operation in routine labs, and clinical research |
Regensburg, Germany | Operational | |||
Micar Innovation (Micar21)Micar Innovation is a drug discovery factory |
Sofia, Bulgaria | Operational | |||
Fabric GenomicsGlobal healthcare platform for genomic data analysis - Formerly Omicia |
San Francisco, United States | Acquired | |||
SoluBestBiotech & Life Sciences |
Ness Ziyyona, Israel | Operational | |||
FF PharmaBiopharmaceutical drug research company |
Utrecht, Netherlands | Operational | |||
CergentisBioinformatical analysis of genes sequencing |
Utrecht, Netherlands | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RatiotxBoston, United StatesSpecializing in the development of targeted radiotherapeutics for the treatment of cancer
$280Mvaluation
Beeline MedicinesStamford, United StatesPrecision therapies for autoimmune and inflammatory diseases.
$1.7Bvaluation
Precede BiosciencesBoston, United StatesLiquid biopsy platform profiling disease-defining transcriptional biology
$254Mvaluation
Link Cell TherapiesSouth San Francisco, United StatesA True CAR T Cell AND-Gate
$120Mvaluation
Orbital TherapeuticsSan Francisco, United StatesAims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease
$1.5Bvaluation
Dispatch BioPhiladelphia, United StatesCloud-powered platform for infectious disease diagnostics
$864Mvaluation
GlycoEraSchlieren, SwitzerlandGlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications
$520Mvaluation
Allyx TherapeuticsNew Haven, United StatesInnovative oral therapies preserving synapses for neurodegenerative disease patients
$106Mvaluation
2seventybioCambridge, United StatesImmuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment
$336Mvaluation
Light Horse TherapeuticsSan Diego, United StatesPrecision gene editing for small molecule drug discovery
$248Mvaluation
Be BioCambridge, United StatesEngineering b cell medicines to improve care for serious diseases
$650Mvaluation
Nuvig TherapeuticsRedwood City, United StatesAdvancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function
$644Mvaluation
Bristol-Myers Squibb in the Lawrence Township ecosystem
The Bristol-Myers Squibb office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
EuroFinance
Series B and later1 investor entered at this stage
Carl Icahn
Other known investors5 additional known investors
Accelerate Okanagan
EW Healthcare Partners
Kleiner Perkins
Medicon Village
RA Capital Management
Source: Dealroom Talent Intelligence.
See Bristol-Myers Squibb’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










